Biomarin Technologies B.V.
6 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Previously recorded as Prosensa Technologies B.V. (to 2015)
10
Ending by 2030
Jul 2028
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jul 14, 2027The maintenance fee for Oligonucleotide comprising an inosine for treating DMD (US 10,533,171) comes due Jul 14, 2027. Unpaid by Jan 14, 2028, it lapses early.
Recent changes
- 1 term has ended since Aug 23, 2026
- Oct 4 US 11,459,358 Substances for Targeting Various Selected Organs or Tissues · lapsed on the fee record
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,519,097 | Molecules for targeting compounds to various selected organs or tissues In force · USPTO record | In force | USPTO record | |
| US 9,499,818 | Methods and Means for Efficient Skipping of at Least One of the Exons 51-53, 55, 57 and 59 of the Human Duchenne Muscular Dystrophy Gene In force · Medium confidence | In force | Medium confidence | |
| US 9,528,109 | METHODS AND MEANS FOR EFFICIENT SKIPPING OF EXON 45 IN DUCHENNE MUSCULAR DYSTROPHY PRE-mRNA In force · Low confidence | In force | Low confidence | |
| US 9,926,557 | METHODS AND MEANS FOR EFFICIENT SKIPPING OF EXON 45 IN DUCHENNE MUSCULAR DYSTROPHY PRE-mRNA In force · High confidence | In force | High confidence | |
| US 10,876,114 | Methods and Means for Efficient Skipping of at Least One of the Following Exons of the Human Duchenne Muscular Dystrophy Gene: 43, 46, 50-53 In force · Medium confidence | In force | Medium confidence | |
| US 11,427,820 | METHODS AND MEANS FOR EFFICIENT SKIPPING OF EXON 45 IN DUCHENNE MUSCULAR DYSTROPHY PRE-mRNA In force · Medium confidence | In force | Medium confidence | |
| US RE48,468 | Means and methods for counteracting muscle disorders In force · USPTO record | In force | USPTO record | |
| US 10,533,171 | Oligonucleotide comprising an inosine for treating DMD In force · USPTO record | In force | USPTO record | |
| US 11,034,956 | Oligonucleotide comprising an inosine for treating DMD In force · USPTO record | In force | USPTO record | |
| US 11,634,714 | Oligonucleotide comprising an inosine for treating DMD In force · USPTO record | In force | USPTO record |
Also on record, not counted in the 14: 6 patents in force now held by others · 5 lapsed for an unpaid fee · 1 surrendered on reissue. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
4 pending · 9 abandoned · 6 no status recorded
Rows 11 to 19 of 19 are for members. The first 10 are on the company page.
Pro members see all 19 published applications.